+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Soft Tissue Sarcomas Market - Global Forecast 2025-2030- Product Image
Soft Tissue Sarcomas Market - Global Forecast 2025-2030- Product Image
Sale

Soft Tissue Sarcomas Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011940
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The soft tissue sarcomas market is navigating significant transformation as advancements in precision medicine, regulatory changes, and dynamic supply chain factors reshape outlooks for senior stakeholders. Strategic collaboration is becoming critical to capitalize on emerging scientific breakthroughs and adapt to complex operational and reimbursement landscapes.

Market Snapshot: Soft Tissue Sarcomas Market Growth and Opportunity

The soft tissue sarcomas market grew from USD 730.82 million in 2024 to USD 805.54 million in 2025. It is expected to continue growing at a CAGR of 9.84%, reaching USD 1.28 billion by 2030. This sustained expansion reflects increased demand for advanced therapeutics and increased focus on holistic patient management. The market offers ample opportunity for biopharma leaders, clinical research organizations, and healthcare systems committed to improving patient outcomes in a complex franchise.

Scope & Segmentation

This report delivers comprehensive coverage of the soft tissue sarcomas market, segmenting the landscape across treatment approaches, disease subtypes, care settings, distribution models, and geographic regions.

  • Treatment Types: Chemotherapy (alkylating agents, anthracyclines, taxanes), combination therapies, immunotherapies (adoptive cell therapies, checkpoint inhibitors), radiation, surgery, and targeted treatments (monoclonal antibodies, mTOR inhibitors, tyrosine kinase inhibitors).
  • Histological Subtypes: Includes fibrosarcoma, leiomyosarcoma, liposarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma, and undifferentiated pleomorphic sarcoma.
  • End Users: Services utilized by ambulatory surgical centers, cancer specialty clinics, home care providers, and hospital systems.
  • Distribution Channels: Hospital pharmacies, online pharmacies, and retail pharmacy partners.
  • Regions: The Americas (notably the United States, Canada, multiple states, and Latin American markets), Europe, the Middle East, Africa, and Asia-Pacific (including China, India, Japan, Australia, and Southeast Asian nations).
  • Leading Companies: Eisai, Janssen Pharmaceutica, Pfizer, PharmaMar, Bayer, Eli Lilly, Adaptimmune Therapeutics, Deciphera Pharmaceuticals, Merck KGaA, and Novartis.

Key Takeaways: Actionable Insights for Senior Decision-Makers

  • Precision medicine is driving a paradigm shift in soft tissue sarcoma care, replacing traditional one-size-fits-all approaches with molecularly targeted therapies that address defined patient subpopulations and enhance treatment outcomes.
  • Collaboration has emerged as a competitive lever, with biotechnology innovators and pharmaceutical leaders forming strategic alliances to access specialized expertise and accelerate pipeline development.
  • Advanced diagnostic tools, including next-generation sequencing, are facilitating earlier identification of actionable mutations and improving trial design by enabling biomarker-driven patient selection.
  • Regional dynamics demand localized strategies, with regulatory requirements, infrastructure capacity, and payer systems varying across Americas, EMEA, and Asia-Pacific territories.
  • Supply chain dependencies and evolving tariff regimes are prompting investments in process innovation, domestic manufacturing, and new sourcing methods to ensure resilience and cost control.
  • Companies leveraging real-world data analytics and companion diagnostics are achieving improved market access positioning and demonstrating added value to both payers and providers.

Tariff Impact

The 2025 United States tariff regime has introduced higher input and manufacturing costs for arisings in soft tissue sarcoma therapeutics production. Stakeholders are shifting toward domestic manufacturing, process optimization, and supplier diversification to reduce vulnerability to global market fluctuations. These efforts can support uninterrupted clinical development and commercial launches but also necessitate significant capital and operational adjustments.

Methodology & Data Sources

This analysis integrates structured interviews with industry, clinical, and reimbursement leaders alongside peer-reviewed literature, proprietary datasets, and regulatory filings. Triangulation of qualitative expert input and real-world data supports robust scenario modeling and independent peer review. This methodology yields actionable insights and supports reliable recommendations for senior decision-making.

Why This Report Matters

  • Enables strategic planning with a clear, data-driven view of trends influencing therapeutic innovation, clinical development, and market entry in the soft tissue sarcomas sector.
  • Supports informed investment by mapping segment-specific opportunities and operational risks across regions and care delivery channels.
  • Guides product positioning and access strategies through insight into collaboration patterns, regulatory evolution, and shifting payer expectations.

Conclusion

Navigating the evolving soft tissue sarcomas landscape demands cross-functional insight and operational agility. The intelligence in this report supports senior leaders in anticipating shifts, prioritizing investments, and driving sustainable advancement in patient care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of comprehensive genomic profiling into personalized soft tissue sarcoma treatment plans
5.2. Adoption of immune checkpoint inhibitor combination regimens in advanced sarcoma subtypes
5.3. Development of NTRK targeted therapies for tissue agnostic treatment of rare sarcoma mutations
5.4. Use of liquid biopsy circulating tumor DNA assays for real time disease progression monitoring
5.5. Expansion of CAR T cell therapy research focusing on novel soft tissue sarcoma specific antigens
5.6. Implementation of AI driven imaging analytics for early detection of sarcoma recurrence risk
5.7. Increasing emphasis on patient reported outcomes and quality of life measures in sarcoma trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Soft Tissue Sarcomas Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Alkylating Agents
8.2.2. Anthracyclines
8.2.3. Taxanes
8.3. Combination Therapy
8.4. Immunotherapy
8.4.1. Adoptive Cell Therapy
8.4.2. Checkpoint Inhibitors
8.5. Radiation Therapy
8.6. Surgery
8.7. Targeted Therapy
8.7.1. Monoclonal Antibodies
8.7.2. mTOR Inhibitors
8.7.3. Tyrosine Kinase Inhibitors
9. Soft Tissue Sarcomas Market, by Histological Subtype
9.1. Introduction
9.2. Fibrosarcoma
9.3. Leiomyosarcoma
9.4. Liposarcoma
9.5. Malignant Peripheral Nerve Sheath Tumor
9.6. Synovial Sarcoma
9.7. Undifferentiated Pleomorphic Sarcoma
10. Soft Tissue Sarcomas Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Cancer Specialty Clinics
10.4. Home Care Settings
10.5. Hospitals
11. Soft Tissue Sarcomas Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacy
11.4. Retail Pharmacies
12. Americas Soft Tissue Sarcomas Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Soft Tissue Sarcomas Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Soft Tissue Sarcomas Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Eisai Co., Ltd.
15.3.2. Janssen Pharmaceutica NV
15.3.3. Pfizer Inc.
15.3.4. PharmaMar, S.A.
15.3.5. Bayer AG
15.3.6. Eli Lilly and Company
15.3.7. Adaptimmune Therapeutics plc
15.3.8. Deciphera Pharmaceuticals, Inc.
15.3.9. Merck KGaA
15.3.10. Novartis AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. SOFT TISSUE SARCOMAS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. SOFT TISSUE SARCOMAS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. SOFT TISSUE SARCOMAS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. SOFT TISSUE SARCOMAS MARKET: RESEARCHAI
FIGURE 24. SOFT TISSUE SARCOMAS MARKET: RESEARCHSTATISTICS
FIGURE 25. SOFT TISSUE SARCOMAS MARKET: RESEARCHCONTACTS
FIGURE 26. SOFT TISSUE SARCOMAS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SOFT TISSUE SARCOMAS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TAXANES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIBROSARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIBROSARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY UNDIFFERENTIATED PLEOMORPHIC SARCOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY UNDIFFERENTIATED PLEOMORPHIC SARCOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 109. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 110. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 111. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 112. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 113. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 114. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 115. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 116. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 117. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 118. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 119. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 126. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 127. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 128. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 129. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 130. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 131. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 196. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 197. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 198. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 199. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 200. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 201. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 202. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 203. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 204. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 205. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 211. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 212. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 213. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 214. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 215. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 216. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 217. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 238. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 239. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 240. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 241. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 242. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 243. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 244. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 245. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 246. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 247. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 252. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 253. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 254. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 255. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 256. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 257. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 258. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 259. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 260. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 261. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 284. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 286. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 288. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 292. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 298. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 299. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 300. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 302. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 308. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 309. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 310. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 311. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 312. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 313. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 314. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 315. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2024 (USD MILLION)
TABLE 316. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2025-2030 (USD MILLION)
TABLE 317. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 322. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 323. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 324. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 325. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 326. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 327. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Soft Tissue Sarcomas market report include:
  • Eisai Co., Ltd.
  • Janssen Pharmaceutica NV
  • Pfizer Inc.
  • PharmaMar, S.A.
  • Bayer AG
  • Eli Lilly and Company
  • Adaptimmune Therapeutics plc
  • Deciphera Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis AG

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 805.54 Million
Forecasted Market Value ( USD ) by 2030 $ 1280 Million
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Soft Tissue Sarcoma - Global Strategic Business Report - Product Image

Soft Tissue Sarcoma - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Sarcoma Biopsy - Global Strategic Business Report - Product Image

Sarcoma Biopsy - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Kaposi Sarcoma Market - Global Forecast 2025-2030 - Product Image

Kaposi Sarcoma Market - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Cancers in the Urban Environment. How Malignant Diseases Are Caused and Distributed among the Diverse People and Neighborhoods of a Major Global Metropolis. Edition No. 2 - Product Image

Cancers in the Urban Environment. How Malignant Diseases Are Caused and Distributed among the Diverse People and Neighborhoods of a Major Global Metropolis. Edition No. 2

  • Book
  • Global
Ewings Sarcoma Treatment Market 2025-2029 - Product Image

Ewings Sarcoma Treatment Market 2025-2029

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.